Literature DB >> 11884333

Commentary: Iloprost for cholesterol emboli syndrome.

Charles D Pusey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884333      PMCID: PMC1122523          DOI: 10.1136/bmj.324.7337.609

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Lesson of the week: cholesterol emboli syndrome.

Authors:  P J Dupont; L Lightstone; E J Clutterbuck; G Gaskin; C D Pusey; T Cook; A N Warrens
Journal:  BMJ       Date:  2000-10-28

2.  Improvement in cholesterol emboli syndrome after iloprost therapy.

Authors:  Eran Elinav; Tova Chajek-Shaul; Mirella Stern
Journal:  BMJ       Date:  2002-02-02

3.  A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.

Authors:  H I Torley; R Madhok; H A Capell; R M Brouwer; P J Maddison; C M Black; H Englert; J A Dormandy; H R Watson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

4.  Improvement in renal cholesterol emboli syndrome after simvastatin.

Authors:  R G Woolfson; H Lachmann
Journal:  Lancet       Date:  1998-05-02       Impact factor: 79.321

5.  Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. U.K. Severe Limb Ischaemia Study Group.

Authors: 
Journal:  Eur J Vasc Surg       Date:  1991-10

6.  Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases.

Authors:  R I Thadhani; C A Camargo; R J Xavier; L S Fang; H Bazari
Journal:  Medicine (Baltimore)       Date:  1995-11       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.